Talk:Atezolizumab

This is the talk page for discussing improvements to the Atezolizumab article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology High‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
High	This article has been rated as High-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Atezolizumab.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Should we mention cost here and or in PD-L1 inhibitors ?

Roche therapy helps 24 percent of untreated bladder cancer patients: study says "At a list price of $12,500 per month, Tecentriq costs roughly the same as [PD-1 inhibitors] Keytruda and Bristol's rival Opdivo" - Should we mention cost here and /or in PD-L1 inhibitors ? - Rod57 (talk) 09:11, 13 June 2016 (UTC)[reply]

Compared with docetaxel chemotherapy

Immunotherapy drug gives non-small-cell lung cancer patients extra four months of life with fewer side effects compared to chemotherapy (or the Lancet source) could be mentioned. - Rod57 (talk) 13:20, 17 December 2016 (UTC)[reply]
Should distinguish the similar OAK and POPLAR trials PD-L1 Inhibitor Wins NSCLC Indication - Rod57 (talk) 13:25, 20 December 2016 (UTC)[reply]

EU approval

Also now approved (full/unconditional?) for "two types of metastatic bladder cancer" says [1] - Need EU RS - Rod57 (talk) 13:22, 1 October 2017 (UTC)[reply]

No confirmatory evidence for FDA approvals

According to FDA says Tecentriq won't lose its bladder cancer nod despite phase 3 failure, Roche reports - Lets see what the FDA say. - Rod57 (talk) 14:21, 5 October 2017 (UTC)[reply]

Name

This article should explain why this drug is named what it is. 2A04:4A43:572F:E992:0:0:2272:ABC8 (talk) 15:44, 29 August 2023 (UTC)[reply]